Nav: Home

The growing role of precision and personalized medicine for cancer treatment

January 28, 2019

In a paper published in the September/December 2018 issue of TECHNOLOGY, a group of researchers from Rutgers University Department of Biomedicine Engineering have published a review paper on the transformative potential of precision and personalized medicine (PPM) for cancer treatment.

A group of Rutgers PhD fellows and faculty published a review paper on the transformative potential of precision and personalized medicine (PPM) for cancer treatment. Their analysis considers the entire process from acquiring PPM data, to developing a PPM product, and addresses broader economic and societal consequences. This review paper is the culminating achievement of a cohort of twelve Ph.D. student fellows at Rutgers University that were funded under the US Department of Education Graduate Training in Emerging Areas of Precision and Personalized Medicine Grant (Award Number P200A150131). Professor Martin Yarmush served as the Program Director and Principal Investigator of the award.

A primary message of the paper is that PPM has the potential to transform cancer care (see image). The traditional model is limited to tumor detection, followed by general treatment procedures such as surgery, chemotherapy, and radiation. In contrast, the PPM approach allows for targeted treatments, which are more effective and avoid unnecessary side effects. These treatments are identified by analyzing specific tissues, gene mutations, and personal factors relevant to each unique case of cancer. Examples of such emerging treatments include immunotherapies, cancer vaccines, companion diagnostics, and more.

In addition, the authors addressed societal issues of PPM in healthcare. Although potentially transformative, a lot of difficult questions must be answered before PPM becomes part of standard cancer care. These include regulatory challenges, economic concerns and feasibility, and associated socioeconomic and privacy issues. Today, PPM technology exists and is rapidly becoming more efficient and sophisticated; however, these questions must be tackled in order to allow for the smooth integration of PPM into cancer care.
-end-
Authors include Paulina Krzyszczyk, Alison Acevedo, Erika J. Davidoff, Lauren M. Timmins, Ile-ana Marrero-Berrios, Misaal Patel, Corina White, Christopher Lowe, Joseph J. Sherba, Clara Hartmanshenn, Kate M. O'Neill, Max L. Balter, Zachary R. Fritz, Ioannis P. Androulakis, Rene S. Schloss & Martin L. Yarmush. All authors are from the Department of Biomedical Engineering and/or the Department of Chemical & Biochemical Engineering at Rutgers.

This work was funded by the Graduate Training in Emerging Areas of Precision and Personalized Medicine Grant (award number P200A150131) from the U.S. Department of Education. We would also like to acknowledge funding from The National Institute of General Medical Sciences (NIH T32 GM008339).

Corresponding author for this review in TECHNOLOGY is Professor Martin Yarmush.

For more insight into the research described, readers are invited to access the www.worldscientific.com/doi/abs/10.1142/S2339547818300020?utm_source=eureka_alert&utm_medium=press_release&utm_campaign=eureka_ TECHNOLOGY ">paper on TECHNOLOGY.

IMAGE

Caption: Traditional versus PPM model for cancer treatment. A comparison of the key differences in the traditional model of cancer treatment and the emerging PPM model. Traditionally, cancer has been treated using general, 'one size fits all' approaches such as chemotherapy, radiation, and surgical excision of tumors. These treatments vary widely in efficacy across individuals and also often cause harm to healthy, non-cancerous organs and tissues. The PPM approach is characterized by individualized treatments tailored to specific tissues, gene mutations, and personal factors relevant to each unique case of cancer. Companion diagnostics help identify which treatments will be most effective for a specific patient's tumor, and novel cell therapies are used to target the cancer with minimal damage to healthy tissues, making the PPM model more effective and safer.

Fashioned as a high-impact, high-visibility, top-echelon publication, this new ground-breaking journal - TECHNOLOGY - will feature the development of cutting-edge new technologies in a broad array of emerging fields of science and engineering. The content will have an applied science and technological slant with a focus on both innovation and application to daily lives. It will cover diverse disciplines such as health and life science, energy and environment, advanced materials, technology-based manufacturing, information science and technology, and marine and transportations technologies.

About World Scientific Publishing Co.

World Scientific Publishing is a leading independent publisher of books and journals for the scholarly, research, professional and educational communities. The company publishes about 600 books annually and about 135 journals in various fields. World Scientific collaborates with prestigious organizations like the Nobel Foundation and US National Academies Press to bring high quality academic and professional content to researchers and academics worldwide. To find out more about World Scientific, please visit http://www.worldscientific.com. For more information, contact Tay Yu Shan at ystay@wspc.com.

World Scientific

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".